Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00589693 · ClinicalTrials.gov registry record · Phase 3
To Compare Safety and Efficacy of Doripenem Versus Imipenem-Cilastatin in Patients With Ventilator-Associated Pneumonia
A Phase 3 study, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- Terminated
- Registry status
- Phase 3
- Development phase
- 274
- Enrollment target
NCT00589693 is a Phase 3 study that was terminated before completion, run by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. The registered enrollment target is 274 participants.
The verdict
NCT00589693, a Phase 3 study, was terminated before completion, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 274 participants
- Enrollment target
Study Summary
The purpose of this study is to show that doripenem is as effective as imipenem-cilastatin in the treatment of patients with ventilator-associated pneumonia.
Interventions
- DRUG Placebo
- DRUG Doripenem
- DRUG Imipenem-Cilastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 274 participants |
| Start Date | 2008-04 |
| Est. Completion | 2011-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00589693
The ClinicalTrials.gov registry entry for NCT00589693 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 274 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00589693 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00589693 about?
NCT00589693 is a clinical study titled "To Compare Safety and Efficacy of Doripenem Versus Imipenem-Cilastatin in Patients With Ventilator-Associated Pneumonia". The purpose of this study is to show that doripenem is as effective as imipenem-cilastatin in the treatment of patients with ventilator-associated pneumonia.
What is the current status of trial NCT00589693?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 274 participants. The study started on 2008-04. Estimated completion is 2011-06.
What interventions are being tested in trial NCT00589693?
The interventions under investigation include: Placebo (DRUG), Doripenem (DRUG), Imipenem-Cilastatin (DRUG).
Who is sponsoring clinical trial NCT00589693?
This trial is sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.